Ginkgo Bioworks Intrinsic Value Calculation – Ginkgo Bioworks to Reveal Q3 Earnings: What’s in Store?
November 9, 2023
🌥️Trending News
Ginkgo Bioworks ($NYSE:DNA) is a leading company in the biotechnology sector, focusing on the development of novel organisms and the engineering of biological systems. The company is also a publicly traded stock on the Nasdaq exchange. As such, investors and analysts alike are eagerly awaiting the release of Ginkgo Bioworks’ Q3 earnings report to gain insight into how the company has been performing. What could this report hold for Ginkgo Bioworks? Analysts are expecting the company to do well, given its growing portfolio of products and services. In particular, investors will be interested in the progress made by Ginkgo’s gene editing technology, as well as its growth in the bioproducts space.
Additionally, investors will be keen to gain insight into how Ginkgo is performing in its corporate partnerships with companies such as Bayer and Cargill. Overall, investors are expecting Ginkgo Bioworks’ Q3 performance to be strong and possibly even exceed expectations. With the amount of innovation and investment in the biotechnology space, Q3 earnings could be a sign of things to come for Ginkgo Bioworks and the industry at large.
Earnings
As GINKGO BIOWORKS is set to reveal its earnings report for FY2023 Q3 on September 30th, investors are wondering what the numbers will show. According to the FY2023 Q2 report as of June 30 2021, the company earned 43.64M USD in total revenue and lost 53.94M USD in net income. This is a 69.8% decrease from the previous year, and a decrease of 80.57M USD from the total revenue recorded three years prior.
With such a significant drop in earnings, GINKGO BIOWORKS will need to have a strong showing in Q3 to start making up the difference. Investors are waiting to see if the company can meet its highest expectations.
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Ginkgo Bioworks. More…
| Total Revenues | Net Income | Net Margin |
| 325.95 | -1.23k | -377.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Ginkgo Bioworks. More…
| Operations | Investing | Financing |
| -297.01 | -47.38 | 95.1 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Ginkgo Bioworks. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.29k | 788.41 | 0.72 |
Key Ratios Snapshot
Some of the financial key ratios for Ginkgo Bioworks are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 106.6% | – | -367.5% |
| FCF Margin | ROE | ROA |
| -113.2% | -48.1% | -32.7% |
Share Price
GINKGO BIOWORKS, a leading bioscience engineering company, is slated to release its third-quarter earnings on Monday. This report follows GINKGO BIOWORKS’ stock opening at $1.7 and closing at $1.5, a 7.3% drop from the previous closing price of 1.6. The earnings report will provide insight into the company’s current financial performance and investor sentiment. Analysts and investors are eager to learn the specifics of GINKGO BIOWORKS’ Q3 earnings, and what they mean for the future of the company. Live Quote…
Analysis – Ginkgo Bioworks Intrinsic Value Calculation
GoodWhale recently conducted an analysis of GINKGO BIOWORKS from a wellbeing perspective. After careful examination of a variety of factors, such as its business model, industry trends, and public sentiment, we came to the conclusion that the fair value of GINKGO BIOWORKS share is approximately $4.2. This figure was determined by our proprietary Valuation Line technique, which employs a variety of algorithms and machine learning models to generate the most accurate assessment. At present, GINKGO BIOWORKS stock is trading at $1.5, a stark contrast to the fair value we have determined. This indicates that GINKGO BIOWORKS share is currently undervalued by 64.3%, making it an attractive investment opportunity for those looking to capitalize on the current market conditions. More…
Peers
The competition among Ginkgo Bioworks Holdings Inc and its competitors is fierce. Abivax SA, Atreca Inc, and Kiromic BioPharma Inc are all vying for a piece of the pie in the biotechnology industry. Ginkgo Bioworks Holdings Inc has a strong hold on the market, but its competitors are quickly catching up.
– Abivax SA ($OTCPK:AAVXF)
Abivax SA is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative therapies with the potential to transform the lives of patients suffering from chronic inflammatory diseases and cancer. The Company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.
Abivax SA has a market cap of 178.76M as of 2022, a Return on Equity of -132.3%. The company’s lead product, ABX464, is a first-in-class, orally-administered, anti-inflammatory and anti-viral small molecule that is currently being evaluated in several Phase II and Phase III clinical trials in ulcerative colitis, Crohn’s disease, and COVID-19. Abivax’s second most advanced product, ABX196, is a first-in-class, anti-cancer, small molecule that targets the p53 protein and is currently being evaluated in a Phase I/II clinical trial in multiple solid tumors.
– Atreca Inc ($NASDAQ:BCEL)
Atreca Inc is a biopharmaceutical company that focuses on the development of antibody-based therapeutics to treat cancer. As of 2022, its market cap is 59.43 million and its ROE is -86.67%. The company’s focus on developing cancer treatments makes it a risky investment, but its potential rewards are high.
– Kiromic BioPharma Inc ($NASDAQ:KRBP)
Kiromic BioPharma Inc is a clinical stage biopharmaceutical company that uses proprietary gene editing platform to develop cancer therapies. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.
Kiromic has a market cap of 5.32M as of 2022 and a Return on Equity of -127.9%. The company’s platform has the potential to edit genes in the body to correct mutations that cause disease. The company’s lead product candidate is KR-330, which is in Phase I/II clinical trials for the treatment of solid tumors.
Summary
Ginkgo Bioworks is an innovative life sciences company focused on using the power of synthetic biology to design and build organisms to address challenges in healthcare, nutrition, clean energy, and more. Investors should closely monitor the company’s upcoming Q3 earnings report, as its performance in this quarter could be indicative of future trends. Analysts should look out for changes in revenue, profit efficiency, sales growth, and other operational metrics to paint a picture of the company’s financial health.
Additionally, investors should also pay attention to any strategic partnerships or new product launches that the company may have announced in the quarter. Finally, they should be aware of any potential macroeconomic changes or industry-wide shifts that could impact Ginkgo Bioworks’ performance. Overall, investors should take all these factors into consideration when analyzing Ginkgo Bioworks’ Q3 earnings report.
